Combination of celecoxib (Celebrex ® ) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.
| Autor: | Dinh TN; Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA)CA 90095, Los Angeles, USA., Onea AS; Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA)CA 90095, Los Angeles, USA., Jazirehi AR; Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA)CA 90095, Los Angeles, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | American journal of clinical and experimental immunology [Am J Clin Exp Immunol] 2017 May 15; Vol. 6 (3), pp. 27-42. Date of Electronic Publication: 2017 May 15 (Print Publication: 2017). |
| Abstrakt: | The nonsteroidal anti-inflammatory drug (NSAID) Celecoxib (Celebrex ® ) received Food and Drug Administration (FDA) approval in 1998 for treatment of osteoarthritis and rheumatoid arthritis, and in recent years, its use has been extended to various types of malignancies, such as breast, colon, and urinary cancers. To maintain the survival of malignant B cells, non-Hodgkin's Lymphoma (NHL) is highly dependent on inflammatory microenvironment, and is inhibited by celecoxib. Celecoxib hinders tumor growth interacting with various apoptotic genes, such as cyclooxygenase-2 (Cox-2), B-cell lymphoma 2 (Bcl-2) family, phosphor-inositide-3 kinase/serine-threonine-specific protein kinase (PI3K/Akt), and inhibitors of apoptosis proteins (IAP) family. CD19-redirected chimeric antigen-receptor (CD19 CAR) T cell therapy has shown promise in the treatment of B cell malignancies. Considering its regulatory effect on apoptotic gene products in various tumor types, Celecoxib is a promising drug to be used in combination with CD19 CAR T cell therapy to optimize immunotherapy of NHL. Competing Interests: None. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|